Press Releases

Find out the latest announcements and updates from Genialis. This is where you’ll find newest reports on our partnerships, collaborations, and achievements.

April 3, 2024|
Genialis Enlists Two New Partners as It Assembles World’s Most Ethno-Geographically Diverse Cancer Data Sets
January 26, 2024|
Genialis and Debiopharm Set Up Biomarker Discovery Collaboration
November 3, 2023|
Genialis Presents Data at SITC 2023 on RNA-Based Biomarkers to Predict Immunotherapy Response
October 23, 2023|
Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers
September 27, 2023|
Genialis Presents ResponderID KRAS, a Biomarker Framework for Predicting Patient Response
September 8, 2023|
Clinical Drug Discovery Veterans Join Genialis’ Efforts to Build Better Biomarkers for Precision Oncology
August 30, 2023|
Genialis Maintains ISO 27001 Information Security Certification for Sixth Year
August 3, 2023|
Genialis and BioLab Win Best Regular Paper at the 21st International Conference of Artificial Intelligence in Medicine
June 13, 2023|
Genialis Presents Poster on KRAS Expression Signature Validation in Lung Cancer

Previous 123 4 5 Next

Media Kit

Boilerplate

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are revolutionizing precision oncology with RNA and AI.

Links & Downloads

Leadership Headshots

Talking Precision Medicine Info Sheet

Leadership Team

linkedin.com/company/genialis

Media Contact

Andrea Vuturo
Vuturo Group for Genialis
andrea@vuturo.com
+1-415-689-8414

New TPM podcast episode! Najat Khan on Recursion’s AI-driven approach to transforming drug discovery across oncology, rare diseases, and more. Tune in to Episode 44 →

New TPM podcast episode! Najat Khan on Recursion’s AI-driven approach to transforming drug discovery across oncology, rare diseases, and more. Tune in to Episode 44 →New TPM podcast episode! Najat Khan on Recursion’s AI-driven approach to transforming drug discovery across oncology, rare diseases, and more. Tune in to Episode 44 →

This website uses cookies and third party services. Read More Accept Reject